These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 35096475)

  • 1. Ketamine Augmentation of Exposure Response Prevention Therapy for Obsessive-compulsive Disorder.
    Bottemanne H; Arnould A
    Innov Clin Neurosci; 2021; 18(10-12):9-11. PubMed ID: 35096475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].
    Bottemanne H; Arnould A; Najar A; Delaigue F; Serresse L; Joly L; Mouchabac S
    Encephale; 2023 Jun; 49(3):304-311. PubMed ID: 37095049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.
    Ferguson AA; Khan AI; Abuzainah B; Chaudhuri D; Khan KI; Al Shouli R; Allakky A; Hamdan JA
    Cureus; 2023 Apr; 15(4):e37833. PubMed ID: 37213965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.
    Martinotti G; Chiappini S; Pettorruso M; Mosca A; Miuli A; Di Carlo F; D'Andrea G; Collevecchio R; Di Muzio I; Sensi SL; Di Giannantonio M
    Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Rodriguez CI; Kegeles LS; Levinson A; Feng T; Marcus SM; Vermes D; Flood P; Simpson HB
    Neuropsychopharmacology; 2013 Nov; 38(12):2475-83. PubMed ID: 23783065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute administration of the NMDA receptor antagonists ketamine and MK-801 reveals dysregulation of glutamatergic signalling and sensorimotor gating in the Sapap3 knockout mouse model of compulsive-like behaviour.
    Gattuso JJ; Wilson C; Hannan AJ; Renoir T
    Neuropharmacology; 2023 Nov; 239():109689. PubMed ID: 37597609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of inhibitory learning theory-based exposure and response prevention and selective serotonin reuptake inhibitor in obsessive-compulsive disorder management: A treatment comparison.
    Samantaray NN; Chaudhury S; Singh P
    Ind Psychiatry J; 2018; 27(1):53-60. PubMed ID: 30416292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review.
    Bandeira ID; Lins-Silva DH; Cavenaghi VB; Dorea-Bandeira I; Faria-Guimarães D; Barouh JL; Jesus-Nunes AP; Beanes G; Souza LS; Leal GC; Sanacora G; Miguel EC; Sampaio AS; Quarantini LC
    Harv Rev Psychiatry; 2022 Mar-Apr 01; 30(2):135-145. PubMed ID: 35267254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine induces immediate and delayed alterations of OCD-like behavior.
    Thompson SL; Welch AC; Iourinets J; Dulawa SC
    Psychopharmacology (Berl); 2020 Mar; 237(3):627-638. PubMed ID: 31927606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive disorder.
    Goodman WK; Grice DE; Lapidus KA; Coffey BJ
    Psychiatr Clin North Am; 2014 Sep; 37(3):257-67. PubMed ID: 25150561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
    Farrell LJ; Waters AM; Boschen MJ; Hattingh L; McConnell H; Milliner EL; Collings N; Zimmer-Gembeck M; Shelton D; Ollendick TH; Testa C; Storch EA
    Depress Anxiety; 2013 Aug; 30(8):723-31. PubMed ID: 23722990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of obsessive-compulsive disorder.
    Seibell PJ; Hollander E
    F1000Prime Rep; 2014; 6():68. PubMed ID: 25165567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mindfulness-based cognitive therapy as an augmentation treatment for obsessive-compulsive disorder.
    Key BL; Rowa K; Bieling P; McCabe R; Pawluk EJ
    Clin Psychol Psychother; 2017 Sep; 24(5):1109-1120. PubMed ID: 28194835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.
    Xia J; Du Y; Han J; Liu G; Wang X
    Drug Des Devel Ther; 2015; 9():2101-17. PubMed ID: 25960632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the addition of cognitive therapy to exposure and response prevention for obsessive compulsive disorder enhance clinical efficacy? A randomized controlled trial in a community setting.
    Rector NA; Richter MA; Katz D; Leybman M
    Br J Clin Psychol; 2019 Mar; 58(1):1-18. PubMed ID: 29984550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure and Response Prevention for Obsessive-Compulsive Disorder: A Case Study of a Veteran With Violent Intrusive Thoughts.
    Siffert V; Riahi C; Stanley MA; Fletcher TL
    J Cogn Psychother; 2019 Feb; 33(1):71-81. PubMed ID: 32746423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure and response prevention for obsessive-compulsive disorder: A review and new directions.
    Hezel DM; Simpson HB
    Indian J Psychiatry; 2019 Jan; 61(Suppl 1):S85-S92. PubMed ID: 30745681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder.
    Sampaio T; Lima C; Corregiari F; Bernik M
    Braz J Psychiatry; 2016; 38(4):287-293. PubMed ID: 27798711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current and emerging features of obsessive-compulsive disorder--trends for the revision of DSM-5].
    Matsunaga H
    Seishin Shinkeigaku Zasshi; 2012; 114(9):1023-30. PubMed ID: 23198591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.